Post-award - Sole Source Justification_Redacted.pdf

This is a Pre-Solicitation Memorandum to the Contract Specialist regarding a restriction of competition for an FDA acquisition.

The FDA Technology Transfer Program seeks to procure FDA marketing data to assess the marketability of FDA inventions. Market research was conducted from June 3-28, 2026, and identified Tradespace.io as the sole source capable of meeting requirements. The requirement encompasses access to a proprietary SaaS platform that integrates real-time market intelligence with patent and IP portfolio analytics, AI-powered invention evaluation, automated commercialization reporting, licensing partner identification, and automated outreach and marketing material generation. The platform must feature private, isolated AI instances to protect pre-patent invention data from public disclosure—a critical requirement for government technology transfer operations. The estimated contract value is not provided in the redacted document, with a base period running from September 30, 2026, to September 29, 2027, and three optional renewal periods extending through September 29, 2030. Performance will be delivered remotely. The market research determined that no other commercially available platform provides this combination of integrated capabilities specifically tailored to government TTP workflows, and no authorized third-party resellers exist. The contracting action is a new contract, and the memorandum justifies sole-source award to Tradespace.io under FAR provisions permitting procurement without full and open competition, citing statutory authority and the unique, proprietary nature of the required capabilities.